MCID: CNN002
MIFTS: 44

Cannabis Abuse

Categories: Mental diseases

Aliases & Classifications for Cannabis Abuse

MalaCards integrated aliases for Cannabis Abuse:

Name: Cannabis Abuse 12 54 15 70
Marijuana Abuse 12 54 70

Classifications:



External Ids:

Disease Ontology 12 DOID:9505
ICD9CM 34 305.2
MeSH 44 D002189
SNOMED-CT 67 268769003 37344009
ICD10 32 F12 F12.1
UMLS 70 C0006868 C0024809

Summaries for Cannabis Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cannabis despite negative consequences.

MalaCards based summary : Cannabis Abuse, also known as marijuana abuse, is related to cannabis dependence and withdrawal disorder. An important gene associated with Cannabis Abuse is CNR1 (Cannabinoid Receptor 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Topiramate and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include eye, cortex and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Cannabis Abuse

Diseases related to Cannabis Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 151)
# Related Disease Score Top Affiliating Genes
1 cannabis dependence 30.2 NRG1 MGLL GABRA2 FAAH COMT CNR1
2 withdrawal disorder 29.9 HTR1A FAAH CNR1
3 polysubstance abuse 29.8 FAAH DRD2 COMT CNR1
4 conduct disorder 29.5 GABRA2 DRD4 DRD2 COMT
5 cocaine dependence 29.4 GABRA2 DRD2 COMT CNR1 BDNF
6 psychotic disorder 29.1 PRODH NRG1 HTR1A DRD4 DRD2 COMT
7 drug dependence 29.0 GABRA2 DRD2 CNR1 BDNF ANKK1
8 antisocial personality disorder 28.9 GABRA2 DRD4 DRD2 COMT ANKK1
9 alcohol use disorder 28.7 PRODH HTR1A GABRA2 DRD2 COMT BDNF
10 personality disorder 28.7 HTR1A DRD4 DRD2 COMT BDNF ANKK1
11 mood disorder 28.5 PRODH HTR1A DRD4 DRD2 COMT CNR2
12 substance dependence 28.5 GABRA2 DRD4 DRD2 COMT CNR1 BDNF
13 substance abuse 28.5 PRODH HTR1A GABRA2 DRD4 DRD2 COMT
14 bipolar disorder 28.1 PRODH NRG1 NGF HTR1A GABRA2 DRD4
15 anxiety 27.8 PRODH NGF HTR1A GABRA2 FAAH DRD4
16 alcohol dependence 27.8 NGF HTR1A GABRA2 FAAH DRD4 DRD2
17 schizophrenia 27.7 PRODH NRG1 NGF HTR1A GABRA2 FAAH
18 attention deficit-hyperactivity disorder 27.4 PRODH NGF HTR1A FAAH DRD4 DRD2
19 autoimmune encephalitis 10.3 FAAH CNR1
20 adrenal gland pheochromocytoma 10.3 NGF BDNF
21 myofascial pain syndrome 10.3 NGF BDNF
22 sexual sadism 10.3 COMT BDNF
23 conversion disorder 10.3 COMT BDNF
24 chronic pain 10.3 COMT CNR1
25 early-onset schizophrenia 10.3 DRD2 BDNF
26 diabetic encephalopathy 10.3 NGF BDNF
27 mild cognitive impairment 10.2 COMT BDNF
28 tendinosis 10.2 CNR1 BDNF
29 schizoid personality disorder 10.2 PRODH DRD2
30 ocular dominance 10.2 NGF BDNF
31 paine syndrome 10.2 NGF COMT BDNF
32 thiamine deficiency disease 10.2 NGF BDNF
33 fibromyalgia 10.2 NGF COMT BDNF
34 schizotypal personality disorder 10.2 PRODH NRG1 COMT
35 brain injury 10.2 DRD2 COMT BDNF
36 detrusor sphincter dyssynergia 10.1 NGF HTR1A
37 chromosomal duplication syndrome 10.1 PRODH NGF BDNF
38 atypical depressive disorder 10.1 HTR1A BDNF
39 opioid addiction 10.1 DRD2 COMT
40 somatization disorder 10.1 HTR1A COMT
41 trigeminal nerve disease 10.1 NGF BDNF
42 intermittent explosive disorder 10.1 HTR1A COMT
43 cocaine abuse 10.1 NGF DRD2 BDNF
44 anterograde amnesia 10.1 HTR1A BDNF
45 hypochondriasis 10.1 HTR1A BDNF
46 severe combined immunodeficiency 10.1
47 kagami-ogata syndrome 10.1 NRG1 DRD2 BDNF
48 retrograde amnesia 10.1 HTR1A BDNF
49 velocardiofacial syndrome 10.1 PRODH NRG1 COMT
50 oculogyric crisis 10.1 PRODH HTR1A

Graphical network of the top 20 diseases related to Cannabis Abuse:



Diseases related to Cannabis Abuse

Symptoms & Phenotypes for Cannabis Abuse

MGI Mouse Phenotypes related to Cannabis Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 BDNF CNR1 COMT DAGLA DRD2 DRD4
2 homeostasis/metabolism MP:0005376 10.1 BDNF CNR1 COMT DAGLA DRD2 DRD4
3 integument MP:0010771 9.81 BDNF CNR1 CNR2 DRD2 FAAH GABRA2
4 nervous system MP:0003631 9.77 BDNF CNR1 COMT DAGLA DRD2 DRD4
5 no phenotypic analysis MP:0003012 9.23 BDNF CNR1 DRD2 GABRA2 HTR1A MGLL

Drugs & Therapeutics for Cannabis Abuse

Drugs for Cannabis Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4 97240-79-4 5284627
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Clozapine Approved Phase 4 5786-21-0 2818
6
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
7
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
8
Methadone Approved Phase 4 76-99-3 4095
9
Haloperidol Approved Phase 4 52-86-8 3559
10
Ondansetron Approved Phase 4 99614-02-5 4595
11
Prazosin Approved Phase 4 19216-56-9 4893
12
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
13
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
14
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
15
Polyestradiol phosphate Approved Phase 4 28014-46-2
16
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
17
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
18 Hypoglycemic Agents Phase 4
19 Psychotropic Drugs Phase 4
20 Dopamine Agents Phase 4
21 Antidepressive Agents Phase 4
22 Cytochrome P-450 Enzyme Inhibitors Phase 4
23 Anti-Anxiety Agents Phase 4
24 Quetiapine Fumarate Phase 4 111974-72-2
25 Antipsychotic Agents Phase 4
26 Dopamine Antagonists Phase 4
27 Gastrointestinal Agents Phase 4
28 Antiemetics Phase 4
29 Cholinergic Agents Phase 4
30 Nicotinic Agonists Phase 4
31 Dermatologic Agents Phase 4
32 Serotonin Uptake Inhibitors Phase 4
33 Haloperidol decanoate Phase 4
34 Adrenergic alpha-Antagonists Phase 4
35 Adrenergic alpha-1 Receptor Antagonists Phase 4
36 Protective Agents Phase 4
37 Respiratory System Agents Phase 4
38 Antidotes Phase 4
39 Antioxidants Phase 4
40 Expectorants Phase 4
41 Anti-Infective Agents Phase 4
42 Antiviral Agents Phase 4
43 N-monoacetylcystine Phase 4
44 Hydrocortisone 17-butyrate 21-propionate Phase 4
45 Hydrocortisone hemisuccinate Phase 4
46 Estradiol 3-benzoate Phase 4
47 Estradiol 17 beta-cypionate Phase 4
48 Neurotransmitter Agents Phase 4
49 Atomoxetine Hydrochloride Phase 4
50 Adrenergic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 366)
# Name Status NCT ID Phase Drugs
1 Clozapine for Cannabis Use Disorder in Schizophrenia Completed NCT01639872 Phase 4 Clozapine;Risperidone
2 Nicotine for Marijuana Withdrawal Completed NCT01400243 Phase 4 Nicotine;Placebo Patch
3 Buspirone Treatment for Marijuana Dependence Completed NCT00875836 Phase 4 Buspirone;Placebo
4 Cannabis and Schizophrenia: Effects of Clozapine Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
5 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Completed NCT01153490 Phase 4
6 Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents Completed NCT00393978 Phase 4 Quetiapine and placebo;Quetiapine and Topiramate
7 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
8 Feasibility and Preliminary Effectiveness of Varenicline for Co-occurring Cannabis and Tobacco Use Completed NCT04595318 Phase 4 Standard clinical care and varenicline
9 Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial Completed NCT03056482 Phase 4 Ondansetron 8mg;Haloperidol 0.05mg/kg;Haloperidol 0.1mg/kg
10 Pilot Study to Assess the Feasibility of Prazosin for Cannabis Use Disorder in Individuals With or Without Post-traumatic Stress Disorder Recruiting NCT04721353 Phase 4 Prazosin Hydrochloride
11 N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms Recruiting NCT03221231 Phase 4 N-acetylcysteine;Placebo Oral Tablet
12 N-Acetylcysteine for Smoking Cessation in Tobacco and Cannabis Co-Use: A Randomized Controlled Trial Not yet recruiting NCT04627922 Phase 4 N-Acetyl cysteine
13 Effects of Cortisol and Estradiol on the Pharmacokinetics of Tetrahydrocannabinol in Women Not yet recruiting NCT04374773 Phase 4 Dronabinol
14 An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse. Terminated NCT00687609 Phase 4 Atomoxetine
15 Reducing Injury, ETOH and THC Use Among ED Patients Unknown status NCT00547963 Phase 2, Phase 3
16 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study to Investigate the Safety and Efficacy of Cannabis Oil in Maintenance Hemodialysis Patients With Protein-energy Wasting Unknown status NCT03664141 Phase 3 Cannabis oil;Placebo/ Regular Oil
17 Evaluation of the Cognitive-behavioral Treatment Programme CANDIS in the German Outpatient Treatment Service System (CANDIS-II) Unknown status NCT00673647 Phase 3
18 Family and Group Therapies for Adolescent Alcohol Abuse Unknown status NCT00484367 Phase 2, Phase 3
19 A Brief Marijuana Intervention for Adolescent Women Completed NCT00227864 Phase 3
20 A Double-Blind Placebo Control Study on the Use of Nabilone for Outpatient Management of Acute Marijuana Withdrawal Completed NCT01025700 Phase 2, Phase 3 Cesemat
21 Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder Completed NCT02803229 Phase 2, Phase 3 Adderall-XR;Matched placebo
22 The Role of Sleep in the Treatment of Cannabis Use Disorders Completed NCT01685073 Phase 2, Phase 3 Zolpidem extended-release
23 A Double Blind, Randomised, Three Way Crossover Study Comparing Two Different Sublingual Cannabis Based Medicine Extracts With Placebo, in Patients With Chronic Pain Due to Brachial Plexus Injury. Completed NCT01606189 Phase 3 GW-1000-02;GW-2000-02;Placebo
24 Reaching and Motivating Change in Teen Marijuana Smokers Completed NCT01109563 Phase 3
25 The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury Completed NCT01555983 Phase 2, Phase 3 Vaporization of Cannabis
26 Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT) Completed NCT01675661 Phase 3 N-Acetylcysteine;Placebo
27 A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence Completed NCT01020019 Phase 2, Phase 3 Dronabinol;Placebo;Lofexidine
28 Nabilone for Cannabis Dependence: A Pilot Study Completed NCT01347762 Phase 2, Phase 3 Nabilone;Placebo
29 Vaping THC From Electronic Cigarettes: a Novel Evaluation of Intake and Pharmacokinetics Completed NCT02955329 Phase 3 Nicotine only;THC only;Nicotine and THC
30 Parallel Groups Study of Divalproex Sodium (Depakote) for Irritable, Explosive Adults & Adolescents Completed NCT00218114 Phase 3 Divalproex Sodium;Placebo
31 Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With Temporomandibular Disorders: a Randomized, Double-blind Study Completed NCT03994640 Phase 2, Phase 3
32 Reducing STIs in Emerging Adults Who Use Alcohol and Marijuana Completed NCT01473719 Phase 3
33 Effect of Cannabis Extract on Acute Radicular Pain and on Analgesic Requirement: A Double Blinded, Randomized, 24 Hours Follow-up Study Recruiting NCT04816994 Phase 3 Single-dose of cannabis oil;Control
34 Substance Misuse To Psychiatric Disorders for Cannabis (SToP-C)--an Early Assertive Pharmacotherapy Intervention Pilot Study Recruiting NCT03485274 Phase 2, Phase 3 Vortioxetine
35 Methodology for Developing an Occlusal Appliance With CBD Active Carrier Recruiting NCT04775030 Phase 2, Phase 3 CBD occlusal appliance
36 N-Acetylcysteine for Youth Cannabis Use Disorder Recruiting NCT03055377 Phase 2, Phase 3 N-acetyl cysteine;Placebo oral capsule
37 Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Active, not recruiting NCT03481959 Phase 3 Methylphenidate
38 Effects of Quetiapine XR in Schizophrenic Patients With Cannabis Abuse and/or Cannabis Induced Psychosis -Pilot Study- Terminated NCT01071135 Phase 3 Quetiapine XR
39 Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Terminated NCT01598896 Phase 2, Phase 3 Dronabinol;Clonidine;Placebo
40 Integration of Internet-facilitated Screening, Brief Intervention, Referral to Treatment (iSBIRT) for Teen Drug Use Into a Pediatric Network Withdrawn NCT01454206 Phase 2, Phase 3
41 Efficacy and Safety of the Hcoil Deep TMS for the Treatment of Cannabis Addiction Unknown status NCT00543036 Phase 1, Phase 2
42 Randomized and Double-blind Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal Unknown status NCT01439828 Phase 2 N-acetylcystein
43 Cannabis Oil for Chronic Non-CancEr Pain Treatment [CONCEPT] - Alpha (α): A Randomized Controlled Trial Unknown status NCT03635593 Phase 2 CBD;CBD+THC
44 A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
45 CANDIS -Targeted Treatment for Cannabis Disorders Unknown status NCT00252980 Phase 2
46 A Phase Ⅱ, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Unknown status NCT03929835 Phase 2 Cannabis oil;Placebo
47 Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study Unknown status NCT02083874 Phase 2 CBD
48 The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer Unknown status NCT03245658 Phase 2 THC and CBD Mixture
49 Marijuana-Abusing Attention Deficit Hyperactivity Disorder (ADHD) Teens: Atomoxetine Treatment Completed NCT00142961 Phase 2 Atomoxetine
50 Dental and Medical Office Internet/Intranet Motivational Enhancement Therapy to Reduce Teen Tobacco, Alcohol, and Drug Use Completed NCT00907309 Phase 1, Phase 2

Search NIH Clinical Center for Cannabis Abuse

Genetic Tests for Cannabis Abuse

Anatomical Context for Cannabis Abuse

MalaCards organs/tissues related to Cannabis Abuse:

40
Eye, Cortex, Brain, Spinal Cord, Prefrontal Cortex, Kidney, Liver

Publications for Cannabis Abuse

Articles related to Cannabis Abuse:

(show top 50) (show all 749)
# Title Authors PMID Year
1
Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. 61 54
16540246 2006
2
Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. 61 54
15500971 2004
3
Marijuana, immunity and infection. 54 61
9610678 1998
4
Polysubstance abuse among sexually abused in alcohol, drug, and gambling addiction treatment in Greenland: a cross sectional study. 61
33250010 2021
5
Cannabis use among Norwegian university students: Gender differences, legalization support and use intentions, risk perceptions, and use disorder. 61
33604449 2021
6
"I have no disease and weed just relaxes me!": The therapeutic challenge in young patients with psychosis and cannabis abuse. 61
33517143 2021
7
3-Year Follow-up of Lower Risk Cannabis Use Patterns: Evidence from a Longitudinal Survey: Suivi de 3 Ans Des Modèles D'usage du Cannabis à Faible Risque : Données Probantes D'une Enquête Longitudinale. 61
33657893 2021
8
Cannabis Abuse and Perioperative Complications Following Inpatient Spine Surgery in the United States. 61
33769411 2021
9
Application of an ultra-performance liquid chromatography-tandem mass spectrometric method for the detection and quantification of cannabis in cerumen samples. 61
33725496 2021
10
Availability of medical cannabis dispensaries and cannabis abuse/dependence-related hospitalizations in California. 61
33565655 2021
11
Recurrent Spontaneous Pneumothorax Associated With Marijuana Abuse: Case Report and Literature Review. 61
33717745 2021
12
The Effect of Cannabis on the Clinical and Cytokine Profiles in Patients with Multiple Sclerosis. 61
33628507 2021
13
Relationship of problematic cannabis use among youth in Spain with perceived risk, environmental factors and sociodemographic factors. 61
32677687 2021
14
The relationship between motivations for cannabis consumption and problematic use. 61
31018002 2021
15
[The use of water pipe and its impact on university students' lifestyle and their psychological distress: a cross-sectional study.] 61
33319772 2020
16
Cannabis induced cardiac arrhythmias: a case series. 61
33442601 2020
17
Coping Strategies and Factors Related to Problematic Substance Use and Behavioral Addictions Among Adolescents and Young Adults with Cancer. 61
32255742 2020
18
Cannabis Abuse or Dependence and Post-operative Outcomes After Appendectomy and Cholecystectomy. 61
32570125 2020
19
The Perceived Stigma of Addiction and Treatment Utilization among Cannabis Addicts in Thailand. 61
33623208 2020
20
Long-term Cognitive, Psychological, and Health Outcomes Associated With Child Abuse and Neglect. 61
32943535 2020
21
What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. 61
32485547 2020
22
Suicide risk among persons living with HIV. 61
32741212 2020
23
Cannabis use during adolescence and the occurrence of depression, suicidality and anxiety disorder across adulthood: Findings from a longitudinal cohort study over 30 years. 61
32379627 2020
24
Cannabis-induced psychosis: clinical characteristics and its differentiation from schizophrenia with and without cannabis use. 61
32677690 2020
25
The association between regular cannabis use, with and without tobacco co-use, and adverse cardiovascular outcomes: cannabis may have a greater impact in non-tobacco smokers. 61
31743053 2020
26
Trend in Hospital Admissions of Drug Addicts and Associated Factors from 2006 to 2015: an Observational Study on the Hospitals' Discharge Registries from a Region of Central Italy. 61
32744296 2020
27
Interaction of Socioeconomic Status with Risky Internet Use, Gambling and Substance Use in Adolescents from a Structurally Disadvantaged Region in Central Europe. 61
32635320 2020
28
Affective Temperament Traits and Age-Predicted Recreational Cannabis Use in Medical Students: A Cross-Sectional Study. 61
32635595 2020
29
Sexual orientation and mental health over the life course in a birth cohort. 61
31190681 2020
30
Cannabis-induced recurrent myocardial infarction in a 21-year-old man: a case report. 61
32617514 2020
31
Prevalence and associated factors of cannabis consumption in medical students: the BOURBON nationwide study. 61
32372364 2020
32
Serotonin Syndrome versus Cannabis Toxicity in the Emergency Department. 61
32426664 2020
33
Rates, predictors and the impact of cannabis misuse on in-hospital outcomes among patients undergoing percutaneous coronary intervention (from the National Inpatient Sample). 61
31922638 2020
34
Region-Wise Distribution of Schizophrenia With Cannabis Abuse and Medication Non-Compliance in the United States: A Nationwide Analysis of 51,975 Hospitalizations. 61
32494541 2020
35
Early 5-HT6 receptor blockade prevents symptom onset in a model of adolescent cannabis abuse. 61
32329240 2020
36
Cannabis Use Disorder and Perioperative Outcomes in Major Elective Surgeries: A Retrospective Cohort Analysis. 61
31789638 2020
37
Psychotic disorders hospitalizations associated with cannabis abuse or dependence: A nationwide big data analysis. 61
31808250 2020
38
Systemic administration with tetrahydrocannabinol causes retinal damage in BALB/c mice. 61
31680560 2020
39
Guided web-based treatment program for reducing cannabis use: a randomized controlled trial. 61
32070417 2020
40
Probability and correlates of transition from cannabis use to DSM-5 cannabis use disorder: Results from a large-scale nationally representative study. 61
31916333 2020
41
Influence of the type of childhood violence on cannabis abuse and dependence among adolescents: a systematic review and meta-analysis. 61
30627731 2020
42
Indirect estimation of student marijuana consumers population in Hamadan using PRM and NSU methods. 61
33500887 2020
43
Intracerebellar Hemorrhage in a Young Adult. 61
32148353 2020
44
Modeling the Comorbidity of Cannabis Abuse and Conduct Disorder/Conduct Problems from a Cognitive Neuroscience Perspective. 61
31608811 2020
45
Secondary spontaneous pneumothorax and bullous lung disease in cannabis and tobacco smokers: A case-control study. 61
32226050 2020
46
Epileptic Spikes in EEG and Migraine Attacks in the Course of Cannabis Withdrawal: A Case Report. 61
31741395 2020
47
Antipsychotic Treatment Failure: A Systematic Review on Risk Factors and Interventions for Treatment Adherence in Psychosis. 61
33162877 2020
48
Disappearance of Tramadol and THC-COOH in Hair After Discontinuation of Abuse. Two Different Profiles. 61
30715334 2020
49
Different Effects of Cannabis Abuse on Adolescent and Adult Brain. 61
32629444 2020
50
[Cannabis, Cannabinoids and Cannabis Use Disorders]. 61
31847034 2019

Variations for Cannabis Abuse

Expression for Cannabis Abuse

Search GEO for disease gene expression data for Cannabis Abuse.

Pathways for Cannabis Abuse

Pathways related to Cannabis Abuse according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 NRG1 NGF NAPEPLD MGLL HTR1A GPR55
2
Show member pathways
13.34 HTR1A GPR55 GABRA2 DRD4 DRD2 CNR2
3 12.19 NGF HTR1A DAGLA COMT CNR1
4
Show member pathways
11.95 NAPEPLD MGLL GABRA2 FAAH DAGLA CNR1
5 11.83 NGF CNR1 BDNF
6 11.74 HTR1A DAGLA CNR1
7
Show member pathways
11.65 HTR1A DRD4 DRD2
8 11.55 GPR55 DRD4 CNR1
9 10.78 DRD2 ANKK1
10 10.78 FAAH CNR2 CNR1
11 10.44 DAGLA CNR1
12
Show member pathways
10.29 HTR1A DRD4 DRD2 COMT

GO Terms for Cannabis Abuse

Cellular components related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.17 NRG1 MGLL HTR1A GPR55 GABRA2 DRD4
2 integral component of plasma membrane GO:0005887 9.86 NRG1 HTR1A GPR55 GABRA2 DRD4 DRD2
3 cell projection GO:0042995 9.85 HTR1A GABRA2 DAGLA CNR2 CNR1 ANKK1
4 synapse GO:0045202 9.8 NRG1 HTR1A GABRA2 DRD2 DAGLA CNR1
5 glutamatergic synapse GO:0098978 9.71 NRG1 DRD4 DRD2 CNR1
6 postsynapse GO:0098794 9.63 GABRA2 DRD4 BDNF
7 axon GO:0030424 9.5 NRG1 NGF GABRA2 DRD2 COMT CNR1
8 GABA-ergic synapse GO:0098982 9.46 NRG1 GABRA2 DRD2 CNR1
9 dendrite GO:0030425 9.23 NGF HTR1A GABRA2 DRD4 DRD2 COMT

Biological processes related to Cannabis Abuse according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.13 HTR1A GPR55 DRD4 DRD2 CNR2 CNR1
2 signal transduction GO:0007165 10.06 NRG1 HTR1A GPR55 GABRA2 DRD4 DRD2
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.83 NRG1 NGF BDNF
4 memory GO:0007613 9.78 NGF CNR1 BDNF
5 modulation of chemical synaptic transmission GO:0050804 9.77 NGF DRD2 BDNF
6 synapse assembly GO:0007416 9.73 NRG1 DRD2 BDNF
7 neurotrophin TRK receptor signaling pathway GO:0048011 9.67 NGF BDNF
8 lipid catabolic process GO:0016042 9.67 NAPEPLD MGLL FAAH DAGLA
9 dopamine receptor signaling pathway GO:0007212 9.66 DRD4 DRD2
10 temperature homeostasis GO:0001659 9.66 NAPEPLD DRD2
11 negative regulation of nitric-oxide synthase activity GO:0051001 9.65 CNR2 CNR1
12 arachidonic acid metabolic process GO:0019369 9.65 MGLL FAAH DAGLA
13 nerve development GO:0021675 9.64 NGF BDNF
14 behavioral response to cocaine GO:0048148 9.64 DRD4 DRD2
15 regulation of synaptic transmission, GABAergic GO:0032228 9.63 DRD2 CNR1
16 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.63 NRG1 DRD4
17 nerve growth factor signaling pathway GO:0038180 9.62 NGF BDNF
18 synaptic transmission, dopaminergic GO:0001963 9.62 DRD4 DRD2
19 negative regulation of voltage-gated calcium channel activity GO:1901386 9.61 DRD4 DRD2
20 regulation of dopamine metabolic process GO:0042053 9.59 HTR1A DRD4
21 positive regulation of collateral sprouting GO:0048672 9.58 NGF BDNF
22 behavioral response to ethanol GO:0048149 9.58 DRD4 DRD2
23 monoacylglycerol catabolic process GO:0052651 9.57 MGLL FAAH
24 negative regulation of mast cell activation GO:0033004 9.55 CNR2 CNR1
25 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.54 DRD4 DRD2
26 negative regulation of action potential GO:0045759 9.52 CNR2 CNR1
27 response to histamine GO:0034776 9.51 DRD4 DRD2
28 response to amphetamine GO:0001975 9.5 DRD4 DRD2 CNR2
29 negative regulation of dopamine secretion GO:0033602 9.49 DRD2 CNR1
30 retrograde trans-synaptic signaling by endocannabinoid GO:0098921 9.46 DAGLA CNR1
31 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.43 DRD4 DRD2
32 peripheral nervous system development GO:0007422 9.43 NRG1 NGF BDNF
33 dopamine metabolic process GO:0042417 9.33 DRD4 DRD2 COMT
34 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.26 HTR1A DRD4 CNR2 CNR1
35 cannabinoid signaling pathway GO:0038171 8.8 GPR55 CNR2 CNR1

Molecular functions related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.85 HTR1A GPR55 DRD4 DRD2 CNR2 CNR1
2 neurotransmitter receptor activity GO:0030594 9.58 HTR1A GABRA2 DRD4
3 acylglycerol lipase activity GO:0047372 9.43 MGLL FAAH
4 dopamine binding GO:0035240 9.32 DRD4 DRD2
5 nerve growth factor receptor binding GO:0005163 9.26 NGF BDNF
6 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD4 DRD2
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.96 DRD4 DRD2
8 cannabinoid receptor activity GO:0004949 8.8 GPR55 CNR2 CNR1

Sources for Cannabis Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....